PI3K and Immune Checkpoint Inhibitor Combination for Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly those targeting the PI3K pathway, face challenges with high toxicity, drug resistance, and side effects, necessitating the development of combinations that can reduce cancer cell growth while minimizing these issues.
Innovation Solution
A combination of a PI3K inhibitor with a second therapeutic agent, such as an immune checkpoint inhibitor or a TGFβ inhibitor, is used to synergistically treat tumors, potentially allowing for lower doses and less frequent administration, thereby reducing toxicity and resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PI3K inhibitors are used to treat tumors, then cancer cell growth is reduced, but toxicity and side effects increase
Solution Approach 1:
The patent combines PI3K inhibitors with immune checkpoint inhibitors or TGFβ inhibitors to create a multi-target therapy approach. This combination allows for synergistic anti-tumor effects while enabling the use of lower doses of each individual agent, thereby reducing toxicity and side effects associated with high-dose monotherapy
2Reliability
If PI3K inhibitors are used to treat tumors, then cancer cell growth is reduced, but drug resistance develops
Solution Approach 1:
The patent employs combination therapy with PI3K inhibitors paired with immune checkpoint inhibitors or TGFβ inhibitors to target multiple pathways simultaneously. This multi-pronged approach prevents cancer cells from developing resistance through single-pathway adaptations, as they must overcome multiple blocked pathways to survive
Solution Approach 2:
The patent utilizes lower doses of PI3K inhibitors in combination with other agents compared to monotherapy. This dose modification changes the therapeutic parameter profile, maintaining efficacy while reducing the selective pressure that drives resistance development
3Reliability
If higher doses of PI3K inhibitors are administered, then tumor treatment efficacy is improved, but frequency and severity of side effects increase
Solution Approach 1:
The patent combines PI3K inhibitors with immune checkpoint inhibitors or TGFβ inhibitors to achieve synergistic effects. This combination therapy enables the use of lower doses of the PI3K inhibitor while maintaining or improving tumor treatment efficacy, thereby reducing the frequency and severity of side effects
Data Source
AI summary
The present application relates to a pharmaceutical combination comprising a phosphoinositide 3-kinase (PI3K) inhibitor and a second therapeutic agent, wherein the second therapeutic agent is an immune checkpoint inhibitor, a TGFβ inhibitor, a bifunctional immune checkpoint/TGFβ inhibitors or combinations thereof. The present application also provides a method of treatment comprising administering the combination, and the use of the drug combination for treating tumors.